Øresund Pharma ApS
APSActiveAdvertising protectionCVR 39492059Orient Plads 1, 2150 NordhavnWholesale of pharmaceutical and medical goods· NACE 4646Est. 2018 · 8 years old21 employeeshttps://www.oresundpharma.com
Loading company…
Overview
Øresund Pharma ApS is a Danish APS based in Nordhavn, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2018, the company has 21 employees and reported a gross profit of DKK 39.7m in its latest annual filing.
Gross profit 2025
39.7M DKK
0% vs 2024
EBITDA margin (of gross profit)
33.7 %
−33% vs 2024
Net profit 2025
6.5M DKK
-53% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
35.0 %
AverageAround the average of companies in the same industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
1.2×
WeakAmong the 40% lowest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
5.1 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
DKK millionsKey figures
Annual report 2025| Gross profit | 39.7M DKK | 0% |
| EBITDA | 13.4M DKK | -33% |
| Net profit | 6.5M DKK | -53% |
| Total assets | 127.6M DKK | +57% |
| Equity | 44.6M DKK | +17% |
| Employees | 21 | — |
Company information
Legal name
Øresund Pharma ApS
CVR number
39492059
Legal form
Anpartsselskab
NACE code
Founded
17 April 2018 · 8 years
Share capital
DKK 55,600
Employees
21 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør alene
Company purpose
Selskabets formål er at udvikle og kommercialisere farmaceutiske lægemidler og dermed forbunden virksomhed.
(no translation available)
Contact
Address
Orient Plads 1, 2150 Nordhavn
Phone
+45 4076 3916
Email
info@oresundpharma.com
Website
https://www.oresundpharma.com
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Øresund Pharma ApS reported a gross profit of DKK 39.7m, broadly in line with the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 6.5m, and the EBITDA margin stood at 33.7%.
At the end of 2025, equity financed 35% of the balance sheet, and current assets covered short-term debt 1.2 times.
Financials
Gross profit
DKK millionsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | 39,702 | 39,622 | 38,260 | 17,238 | 7,275 |
| Staff expenses | -26,321 | -19,757 | -15,090 | -10,055 | -5,576 |
| EBITDA | 13,381 | 19,865 | 23,169 | 7,183 | 1,699 |
| Depreciation & amort. | -4,248 | -2,229 | -1,228 | -1,065 | -889 |
| EBIT | 9,133 | 17,636 | 21,942 | 6,118 | 810 |
| Net financials | -774 | -1 | -459 | -595 | -398 |
| Profit before tax | 8,358 | 17,634 | 21,483 | 5,523 | 412 |
| Tax | 1,891 | 3,927 | 4,732 | 1,221 | 131 |
| Net profit | 6,467 | 13,707 | 16,751 | 4,302 | 281 |
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 127,580 | 81,089 | 42,518 | 30,951 | 23,913 |
| Equity | 44,618 | 38,151 | 24,443 | 7,692 | 3,390 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 82,784 | 42,863 | 18,075 | 23,258 | 20,499 |
| Total debt | 82,784 | 42,863 | 18,075 | 23,258 | 20,499 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
33.7 %
20212025
Equity ratio
35.0 %
AverageAround the average of companies in the same industry
20212025
Return on equity
14.5 %
AverageAround the average of companies in the same industry
20212025
Net profit margin (of gross profit)
16.3 %
20212025
Asset turnover (of gross profit)
0.31×
20212025
Debt / equity
1.86×
WeakAmong the 40% lowest rated companies in the industry
20212025
Sector performance
23 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Average
Around the average of companies in the same industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Average
Around the average of companies in the same industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Average
Around the average of companies in the same industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioStrong
Among the 40% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Liquidity
Current ratioWeak
Among the 40% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 20% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 40% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalWeak
Among the 30% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 20% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioAverage
Around the average of companies in the same industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioAverage
Around the average of companies in the same industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityWeak
Among the 40% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityWeak
Among the 40% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtAverage
Around the average of companies in the same industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageAverage
Around the average of companies in the same industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtWeak
Among the 40% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginStrong
Among the 40% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityStrong
Among the 30% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SA Management | Management | 2024 |
PH Chief Executive Officer | Chief Executive Officer | 2018 |
Board of directors
Non-executive oversightNo data on file.
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 90–99.99% | 90–99.99% | 2020 | |
| Company | 10–14.99% | 10–14.99% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Related companies
Company hierarchy
Machpali ApS
Øresund Pharma ApS Board network connections
Board members of Øresund Pharma ApS also hold positions in 10 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Svend Aage Johansen | Management | 7 companiesMany roles |
| Patrick Halborg Cohn | Chief Executive Officer | 3 companies |
Frequently asked questions
What is the CVR number of Øresund Pharma ApS?
Øresund Pharma ApS is registered with CVR / Virk under CVR 39492059.
What is the gross profit of Øresund Pharma ApS?
Øresund Pharma ApS reported a gross profit of DKK 39.7m in 2025.
How many employees does Øresund Pharma ApS have?
Øresund Pharma ApS employs 21 people as of the latest annual report.
Who is the CEO of Øresund Pharma ApS?
Patrick Halborg Cohn is the CEO of Øresund Pharma ApS.
Where is Øresund Pharma ApS headquartered?
Øresund Pharma ApS's registered address is Orient Plads 1.